Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: Effect of triglyceride reductions with atorvastatin

Metabolism: Clinical and Experimental

Volumn 49, Issue 2, 2000, Pages 167-177

  Le, Ngoc Anh ^a,b   Innis Whitehouse, Wendy ^a,b   Li, Xianzhou ^a,b   Bakker Arkema, Rebecca ^a,b   Black, Donald ^a,b   Brown, W Virgil ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FAST PROTEIN LIQUID CHROMATOGRAPHY; GEL ELECTROPHORESIS; HUMAN; HYPERTRIGLYCERIDEMIA; PARTICLE SIZE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0033973214     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(00)91169-7     Document Type: Article

References (41)

1. Illingworth DR Tolbert JA A review of clinical trials comparing HMG-CoA reductase inhibitors Clin Ther 16 1994 336 385
2. Schonfeld G HMG CoA reductase inhibitors LaRosa JC Practical Management of Lipid Disorders 1992 Healthcare Communication Washington, DC 75 90
3. Grundy SM: HMG CoA reductase inhibitors: Clinical applications and therapeutic potentials, in Rifkind BM (ed): Drug Treatment of Hyperlipidemia. New York, NY, Dekker, pp 139–167
4. Gianturco SH Bradley WA Nozaki S Effects of lovastatin on the levels, structure and atherogenicity of VLDL in patients with moderate hypertriglyceridemia Arterioscler Thromb 13 1993 472 481
5. Vega GL Krauss RM Grundy SM Pravastatin therapy in primary moderate hypercholesterolemia: Changes in metabolism of apoB-containing lipoproteins J Intern Med 227 1990 81 94
6. Brown WV Howard WJ Field L Nicotinic acid and its derivatives Rifkind BM Drug Treatment of Hyperlipidemia 1990 Dekker Fort Lee, NJ 185 196
7. Hunninghake DB Peters J Effects of fibric acid derivatives on blood lipids and lipoprotein levels Am J Med 83 suppl 5B 1987 44 49
8. Jacobson TA Amorosa LF Combination therapy with fluvastatin and niacin in hypercholesterolemia Am J Cardiol 73 1994 25D 29D
9. East C Bilheimer DW Grundy SM Combination drug therapy for familial hyperlipidemia Ann Intern Med 109 1988 25 32
10. Nawrocki JW Weiss SR Davidson MH Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor Arterioscler Thromb Vasc Biol 15 1995 678 682
11. Bakker-Arkema R Davidson M Goldstein R Efficacy and safety of a new HMG CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia JAMA 275 1995 128 133
12. McConathy WJ Gesquire JC Bass H Inhibition of lipoprotein lipase by synthetic peptides of apoC-III J Lipid Res 33 1992 995 10003
13. Ginsberg HN Le N-A Wang-Iverson P Apolipoprotein metabolism in subjects with deficiency of apoC-III and A-1: Evidence that apoC-III inhibits lipoprotein lipase in vivo J Clin Invest 78 1986 1287 1295
14. Windler E HAvel RJ Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver J Lipid Res 26 1985 556 565
15. Kowal RC Herz J Weisgraber KH Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor—related protein J Biol Chem 265 1990 10771 10779
16. de Silva HV Lauer SJ Wang J Overexpression of human apoC-III in transgenic mice results in an accumulation of apoB-48 remnants that is corrected by excess apoE J Biol Chem 269 1994 2324 2335
17. 2-macroglobulin receptor J Biol Chem 266 1991 13936 13940
18. Ginsberg HN Le N-A Gibson JC Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects: Effect of weight loss J Clin Invest 75 1985 614 623
19. Nishiwaski M Ishikawa T Homma Y Effects of pravastatin on plasma lipids, apolipoproteins, Lp(a), remnant-like particle, cholesteryl ester transfer protein, and lecithin:cholesterol acyltransferase; a 12-month study Nutr Metab Cardiovasc Dis 4 1994 10 15
20. Alaupovic P Hodis HN Knight-Gibson C Effect of lovastatin on apoA- and apoB-containing lipoproteins Families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS) Arterioscler Thromb 14 1994 1906 1914
21. Broyles FE Walden CE Hunninghake D Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia Am J Cardiol 76 1995 129A 135A
22. Innis-Whitehouse W Li X Brown WV An efficient chromatographic system for lipoprotein fractionation using whole plasma J Lipid Res 39 1998 679 690
23. Gibson JC Rubinstein A Bukberg PR Apolipoprotein E—enriched lipoprotein subclasses in normolipidemic subjects J Lipid Res 24 1983 886 898
24. Tornoci L Sheraldi CA Li X Abnormal activation of lipoprotein lipase by non-equilibrating apoC-II: Further evidence for the presence of non-equilibrating pools of apoC-II and C-III in plasma lipoproteins J Lipid Res 34 1993 1793 1803
25. Li X Innis-Whitehouse W Brown WV Simultaneous determination of Lp(a), LDL and HDL particle sizes by segmental nondenaturing gradient gel electrophoresis J Lipid Res 38 1997 2603 2614
26. Tato F Vega GL Tall AR Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia Arterioscler Thromb Vasc Biol 15 1995 112 120
27. Tato F Vega GL Grundy SM Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations Arterioscler Thromb Vasc Biol 15 1995 446 451
28. Albers JJ Tollefson JH Chen C-H Isolation and characterization of human plasma lipid transfer proteins Arteriosclerosis 4 1984 49 58
29. Traber MG Kayden HJ Inhibition of cholesterol synthesis by mevinolin stimulates LDL receptor activity in human monocyte—derived macrophages Atherosclerosis 52 1984 1 11
30. Reihner E Rudling M Stahlnerg D Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol N Engl J Med 323 1990 224 228
31. Kervinen K Savolainen MJ Heikkila JI Lovastatin enhances hepatic uptake of low density lipoprotein in humans J Lipid Res 34 1993 1975 1982
32. Bilheimer DW Grundy SM Brown MS Mevinolin and cholestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes Proc Natl Acad Sci USA 80 1983 4124 4128
33. Arad Y Ramakrishnan R Ginsberg HN Effects of lovastatin therapy on VLDL triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of TG-rich lipoproteins Metabolism 41 1992 488 493
34. Kasim SE LeBoeuf RC Khilnani S Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat J Lipid Res 33 1992 1 7
35. (abstr) Le N-A Innis W Umeakunne K Accelerated clearance of postprandial lipoproteins with HMG CoA reductase inhibitor J Invest Med 43 1995 301A
36. Guerin M Bruckert E Dolphin PJ Fenofibrate reduces plasma cholesteryl ester transfer from HDL or VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia Arterioscler Thromb Vasc Biol 16 1996 763 772
37. Yuan J Tsai MY Hunninghake DB Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy Ahterosclerosis 110 1994 1 11
38. Fredenrich A Giroux LM Tremblay M Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: Comparison of the apoC-III to apoE ratio in different lipoprotein fractions J Lipid Res 38 1997 1421 1432
39. McPherson R Mann CJ Tall AR Plasma concentrations of CETP in hyperlipoporteinemia: Relation to cholesteryl ester protein activity and other lipoprotein variables Arterioscler Thromb 11 1991 797 804
40. Ahnadi CE Berthezene F Ponsin G Simvastatin-induced decrease in the transfer of cholesterol esters from high density lipoproteins to low density lipoproteins in normolipidemic subjects Atherosclerosis 99 1993 219 228
41. (abstr) Sweeney ME Le N-A Li X Effect of weight loss on LDL particle size and postprandial lipemia in obese subjects with CAD Circulation 88 1993 1364